PUBLIC COMPANY
save$LXEOLexeo Therapeutics, Inc.
$LXEONew York, NY, USupdated 21d ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Clinical Course Of Disease In Participants With FA-CM
- phase2Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
- —Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
- phase2Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
- phase2Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
- phase1Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
- —A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 6, 26SELLTownsend Richard Nolan· Chief Executive Officer−$313K↗
routine RSU / option mechanics (2)
- Mar 13, 26grantOtero Jose Manuel · Chief Operating Officer5,930 sh
- Mar 13, 26grantTownsend Richard Nolan · Chief Executive Officer2,623 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that